Soleno Therapeutics (SLNO) Share-based Compensation (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Share-based Compensation data on file, last reported at $16.1 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $16.1 million, up 9.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.2 million (down 56.35% YoY), and the FY2025 annual result was $45.8 million, down 54.13% from the prior year.
• Share-based Compensation grew to $16.1 million in Q1 2026 per SLNO's latest filing, from $11.5 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $56.6 million in Q3 2024 and troughed at $571000.0 in Q2 2022.
• A 5-year average of $10.0 million and a median of $6.4 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 2471.47% in 2024, then tumbled 82.34% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $632000.0 in 2022, then soared by 202.06% to $1.9 million in 2023, then jumped by 1458.67% to $29.8 million in 2024, then tumbled by 61.45% to $11.5 million in 2025, then jumped by 39.97% to $16.1 million in 2026.
• Business Quant data shows SLNO's Share-based Compensation at $16.1 million in Q1 2026, $11.5 million in Q4 2025, and $10.0 million in Q3 2025.